.css-12qhwz2{background:url(https://backend.arctic-bioscience.com/wp-content/uploads/2021/04/cloud-download.png) no-repeat;float:left;width:24px;height:24px;margin-right:10px;}Presentation – ABS Capital Market Update 21 September 2022
September 21, 2022 at 06:50 am
Share
Arctic Bioscience
Company Presentation
Capital Markets Update, Oslo 21 September 2022
Christer L. Valderhaug (CEO)
Developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds, utilizing proprietary technology and methodology
Agenda
Introduction and company presentation - Christer Valderhaug, CEO Arctic Bioscience
Psoriasis symptom relief through Herring Caviar Oil - Dr. Kåre Steinar Tveit, Chief Physician Haukeland University Hospital
Arctic Bioscience Pharmaceutical Development Program - Runhild Gammelsæter, Medical Director Arctic Bioscience
Brain development in extremely premature infants - Knut Smerud, Founder & CEO Smerud Medical Research
DHA, Alfa & Omega for The Brain - Ole Petter Hjelle, MD PhD
Closing remarks & Q&A - CEO Christer Valderhaug, Medical Director Runhild Gammelsæter, CFO Jone Slinning
Lunch and social
Two unique businesses built upon a proprietary technology and IP platform
NUTRA
Premium Omega-3 products with benefits for brain, heart, eye health, prenatal and sports nutrition in global markets
PHARMA
Drug candidate for mild to moderate psoriasis with demonstrated promising effect in pilot clinical trial
Orphan drug candidate in pipeline for brain development in extremely premature children
TECHNOLOGY / R&D
Proprietary technology platform and specialized know-how of bioactive marine compound
Founding story: Arctic Bioscience
2011-2016: Laying the foundation
2011
2012
Arctic Bioscience is
Pharmaceutical
founded
potential of products
discovered
2017-2022: Building the foundation framework for a robust clinical program
2017
2019
2020
2020
Pilot clinical
Pilot clinical
First clinical
Scientific
trial initiated
trial
study results
Advice from
completed
published
the EMA
2021
2022
Strategic
B2C
Dr. Mercola
IPO
HRO350
partnership
B2B bulk sales
subscription is
sales in USA pass
entered with
surpass NOK
launched in
3m in single
Euronext
Phase IIb
Kotler
20m
Norway
order
Growth, Oslo
Scaling Nutra
2019
2019
2020
2020
globally
2019-2022: Developing the organization to prepare for future growth
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Arctic Bioscience AS published this content on 21 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 September 2022 10:49:05 UTC.
Arctic Bioscience AS is a Norway-based biotech company developing and commercializing both pharmaceutical and nutraceutical products based on the properties of herring roe oil. Arctic Bioscienceâs purpose is to provide people with autoimmune disorders an effective and healthy therapy based on marine membrane lipids. The Company is developing HRO350 - a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. The Company's product portfolio includes, among others, Romega, which is a producer of an omega-3 dietary supplement made from herring roe in a form of a capsule, as well as herring caviar oil and herring caviar protein offered to Business-to-Business (B2B) customers. Arctic Bioscience AS has three subsidiaries Arctic Nutrition AS, Romega AS and Arctic Biopharma AS.
ARCTIC BIOSCIENCE 
